This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

ICAD Reports Third Quarter Financial Results

The goodwill impairment and gain on contingent consideration are non-cash items and are excluded from the non-GAAP financial results. A further discussion of our non-GAAP results for the third quarter and first nine months of fiscal 2011 is included elsewhere in this press release.

Net Loss: For the third quarter of 2011, the Company posted a net loss of $25.0 million, or $0.46 per share, compared with a net loss of $1.4 million, or $0.03 per share, in the third quarter of 2010.

Non-GAAP Adjusted Net Loss: For the third quarter of 2011, the Company posted a non-GAAP adjusted net loss of $1.8 million, or $0.03 per share, compared with a net loss of $1.7 million, or $0.04 per share, in the third quarter of 2010.

Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA was a loss of $868,000 in the third quarter of 2011, compared with a loss of $1.0 million in the third quarter of 2010.

Cash and Cash Flow: The Company ended the third quarter of 2011 with cash and cash equivalents of $5.3 million and no long-term debt. For the 2011 third quarter, net cash used by operations was $2.3 million.

Nine Month Financial Results

Revenue: For the nine months ended September 30, 2011, total revenue was $22.0 million, an increase of $3.8 million, or 21%, compared with total revenue of $18.2 million for the nine months ended September 30, 2010. The Axxent eBx system contributed approximately $4.3 million to revenue in the first nine months of 2011, consisting of approximately $3.1 million in product sales and $1.2 million in service and supply revenue.

     
Nine months ended September 30,
2011   2010   % Change
Digital & MRI revenue $ 10,751 $ 11,468 (6 )%
Film based revenue 1,670 2,519 (34 )%
Electronic brachytherapy 3,042 - -
Service & supply revenue   6,579     4,217   56 %
Total revenue $ 22,042   $ 18,204   21 %
 

Gross Margin: Gross profit for the first nine months of 2011 was $15.5 million, or 70.4% of revenue, compared with $14.6 million, or 80.4% of revenue, for the first nine months of 2010. The 2011 nine-month gross margin was impacted by $700,000 of amortization expense and higher manufacturing costs, both related to the Axxent eBx product.

Net Loss: For the first nine months of 2011, the Company posted a net loss of $34.3 million, or $0.63 per share, compared with a net loss of $3.3 million, or $0.07 per share, for the first nine months of 2010.

Non-GAAP Adjusted Net Loss: For the first nine months of 2011, the Company posted a non-GAAP adjusted net loss of $9.9 million, or $0.18 per share, compared with a net loss of $3.6 million, or $0.08 per share for the nine months ended September 30, 2010.

Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA was a loss of $6.8 million for the nine months ended September 30, 2011, compared with a loss of $1.1 million for the nine months ended September 30, 2010.

Financial Guidance

iCAD today confirmed financial guidance for 2011 and continues to expect total revenue to be in the range of $30 million to $32 million, with gross margin between 71% and 73%.

Stock quotes in this article: ICAD 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs